Table 2.

Baseline characteristics of KTRs explored according to the immunosuppressive regimen

Baseline CharacteristicsGroup 1: Tacrolimus-Based IS Regimen, n=24P ValueaGroup 2: Belatacept-Based IS Regimen, n=10P ValuebGroup 3: Nontacrolimus- and Nonbelatacept-Based IS Regimen, n=11P Valuec
Age, yr60.2±17.40.2168.1±13.70.8266.6±15.50.29
Sex (M/W), n12/120.596/40.515/6
Time from transplantation, yr6.1±4.90.926.3±4.70.00117.1±7.9<0.001
eGFR, ml/min per 1.73 m245.6±13.70.00530.4±11.60.00750.1±17.40.41
Induction therapy for KT, n (%)
 ATG11 (45.8)0.162 (20)0.215 (45.5)
 Anti–R-IL213 (54.2)8 (80)6 (54.5)
IS regimen, n (%)
 Tacrolimus24 (100)<0.0010<0.0010<0.001
  C0 tacrolimus6.1±1.80.0070.54<0.001
 Cyclosporin00.7800.698 (72.7)0.05
  C0 cyclosporin0.140.4867.2±15.30.26
 MMF23 (95.8)0.126 (60)0.608 (72.7)0.56
 MMF median of dosage, mg1000<0.01625<0.00110000.03
 AZA1 (4.2)0.132 (20)0.121 (9.1)0.77
 Everolimus01 10)2 (18.2)
 Belatacept010 (100)0
 Steroids10 (41.7)7 (70)4 (36.4)
  • IS, immunosuppressive; M, men; W, women; KT, kidney transplantation; ATG, antithymoglobuline; R-IL2, IL-2 receptor; C0, through level; MMF, mycophenolate mofetil; AZA, azathioprine.

  • a Comparison between groups 1 and 2.

  • b Comparison between groups 2 and 3.

  • c Comparison between groups 1 and 3.